Delay brings success for Roche as it finally wins FDA nod for Tecentriq regimen in frontline lung cancer
Roche’s eagerly-anticipated approval for a combination of its immunotherapy Tecentriq and anti-VEGF Avastin in addition to chemotherapy in frontline lung cancer is finally here — the FDA sanctioned the approval on Thursday after initially delaying its decision.
The Swiss drugmaker will now do its best to carve itself a bigger piece of the lucrative oncology market, which is already largely divided between leaders Merck $MRK and Bristol-Myers Squibb $BMY, which have long established their respective checkpoint inhibitors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
